Global molecular diagnostics company Genetic Signatures (ASX: GSS) has decided to halt the development of its EasyScreen Essentials Respiratory Detection Kit for the US market due to increased competition and changing market dynamics. It will now focus its effort and investment on the anticipated launch of the EasyScreen Gastrointestinal Parasite Detection Kit in the US.
Read More
Flu season is around the corner, typically affecting us between May and September. Just in time for that, Australian global molecular diagnostics company Genetic Signatures (ASX: GSS) is gearing up to launch its modified respiratory kit in the country. The Company reported that the Therapeutic Goods Administration (TGA) has completed the review of its redesigned
Read More
Gastrointestinal (GI) parasites are a pressing public health issue, affecting both humans and animals. Unfortunately, these diseases often go undiagnosed due to limited awareness among healthcare providers and the lack of available diagnostic tests. In the US, undiagnosed GI cases impact at least 12 million Americans, causing health problems either through new infections or long-lasting
Read More
Every day there are more than 1 million sexually transmitted infections (STI) contracted, but biotech company Genetic Signatures (ASX: GSS) will play a key role in reducing those numbers, having secured regulatory approval in Europe for their testing kit which can simultaneously test for 10 of the most common STIs, rapidly. The 3base™ EasyScreenTM STI
Read More
Biotech company Genetic Signatures (ASX: GSS) is poised to play a major role in flattening the curve of coronavirus cases in Australia after the Therapeutics Goods Association (TGA) approved their SARS-CoV-2 Detection Kit for sale in Australia. Regulatory approval in Australia follows authorisation which was granted in Europe 10 days ago with Genetic Signatures able
Read More